|
 The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has formally announced the opening of the stall retention and fresh booking process for iPHEX 2026, the 12th edition of the International Exhibition on Pharmaceuticals and Healthcare Industry.
The event is scheduled to take place between September 7 and September 9, 2026, at Bharat Mandapam in New Delhi.
Organized by Pharmexcil with support from the union ministry of commerce and industry, Government of India, iPHEX 2026 is expected to draw more than 400 overseas business delegates from regions including North American Free Trade Agreement (NAFTA), the European Union, Africa, Association of Southeast Asian Nations (ASEAN), Commonwealth of Independent States (CIS), South Asia, Latin America and Caribbean (LAC), Oceania, and West Asia and North Africa (WANA).
The exhibition floor at Bharat Mandapam will host over 1,000 stalls, making it one of the most extensive showcases of India’s pharmaceutical sector on a single platform.
Over the past decade, iPHEX 2026 has evolved into a premier global platform that connects India’s pharmaceutical capabilities with international markets. The upcoming edition continues this trajectory, promising wider participation, deeper engagement, and expanded opportunities for exporters and buyers.
Speaking on the announcement, Pharmexcil director general (DG) Raja Bhanu emphasized the scale and significance of the forthcoming edition, stating, “iPHEX 2026 will showcase India’s expanding strength in pharmaceuticals and healthcare, bringing the world’s leading buyers, regulators, and industry partners under one roof.”
Companies from across the healthcare and life sciences value chain will be represented, including those engaged in formulations, APIs, intermediates, excipients, vaccines, biotech products, veterinary, Ayush, medical devices, diagnostics, surgical products, CRO/CDMO/R&D services, healthcare and digital health technologies.
This diversity highlights India’s growing capability to deliver across traditional and emerging segments of global healthcare demand.
One of the core attractions of iPHEX 2026 will be its three days of structured B2B meetings, enabling Indian exporters to directly engage with international buyers, regulatory agencies, and global procurement organizations. These curated interactions have been a hallmark of iPHEX, facilitating sustained business partnerships and opening new market avenues.
With both stall retention for previous exhibitors and fresh bookings now open, Pharmexcil has urged companies to secure their space early, given the high demand expected for the 2026 edition.
“iPHEX 2026 is poised to reaffirm India’s position as a trusted global supplier of quality pharmaceuticals and healthcare innovations while offering an unmatched platform for industry collaboration and growth,” Pharmexcil DG stated.
|